Cost-effectiveness of Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the Republic of Korea

Park, Hae Young; Ku, Hyemin; Sohn, Hyun-Soon; Seo, Haesook; Lee, Hyun Yung; Lim, Kyung Hwa

doi:10.1016/j.clinthera.2016.01.023

Cited by 13 publications

(28 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study findings were consistent with recent cost-effectiveness analyses in the Republic of Korea and Germany, in which B-BR was accepted as cost-effective with more QALYs gained at additional cost. The comparable cost-effectiveness findings are possibly related to similar WTP thresholds applied for the acceptance of costeffectiveness (USD 46 182/QALY in Hong Kong; USD 23 636/QALY in Korea; USD 35 431-59 053/QALY in Germany), as well as the well-established healthcare systems in these developed regions (Park et al, 2016;Wirth et al, 2017).…”

Section: Discussionmentioning

confidence: 61%

“…The World Health Organization (WHO) subsequently recommended bedaquiline and delamanid as add-on agents to a WHO-recommended regimen in adult patients with MDR-TB (World Health Organization, 2013. In clinical studies, the use of bedaquiline or delamanid as add-on therapy to BR for MDR-TB has shown significant bactericidal activity and improved tolerability (Pontali et al, 2016;Sotgiu et al, 2015), yet the cost-effectiveness of adding bedaquiline or delamanid to BR has varied in different countries (subject to drug cost and healthcare resource variations) (Diel et al, 2015;Lu et al, 2017;Park et al, 2016;Wirth et al, 2017;Wolfson et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China

Fan

Ming

Yip

et al. 2019

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Objective: Hong Kong is a high-income city of China with an intermediate tuberculosis (TB) burden, and 1% of TB cases are multidrug-resistant (MDR-TB). The aim of this study was to examine the potential costeffectiveness of adding bedaquiline or delamanid to the background regimen (BR) for the treatment of MDR-TB in Hong Kong. Methods: A decision-analytic model was designed to simulate outcomes over a 10-year time horizon for MDR-TB patients treated with bedaquiline plus BR (B-BR), delamanid plus BR (D-BR), or BR alone. Outcome measures included direct medical costs and quality-adjusted life-years (QALYs) gained. Results: In the base-case analysis, BR was the least costly regimen (USD 47 396) with the lowest QALYs gained (6.347). Compared to BR, B-BR gained an additional 0.731 QALYs with incremental cost of USD 9. The incremental cost-effectiveness ratio (ICER) of B-BR was USD 12/QALY. D-BR was more costly than BR by USD 20 164 and gained an additional 0.012 QALYs. The ICER of D-BR was USD 1 680 333/QALY. In the probabilistic sensitivity analysis with 10 000 Monte Carlo simulations, B-BR and D-BR were cost-effective 99.98% and 5.13% of the time, respectively, using 1Â gross domestic product per capita (USD 46 182) as the willingness-to-pay threshold. Conclusions: Bedaquiline is more likely than delamanid to be cost-effective when added to BR for the treatment of MDR-TB in Hong Kong.

show abstract

Section: Discussionmentioning

confidence: 61%

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China

Fan

Ming

Yip

et al. 2019

International Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…Intervention type outcome in the assessment, and 11 did not provide separate results according to both perspectives so it was not possible to extract the data from the results. Hence, 14 articles satisfied all the inclusion criteria [27][28][29][30][31][32][33][34][35][36][37][38][39][40][32][33][34][35][36][37][38][39][40][41][42][43][44][45] and were finally included. With respect to the perspective used in the studies included in the review, half of the studies used both that of the healthcare payer and the wider perspective (the societal approach) in the analyses.…”

Section: Diseasementioning

confidence: 99%

“…40,[42][43][44][45] On the other hand, 2 studies used the healthcare provider's perspective as the main perspective but included the societal perspective in the sensitivity analysis. 34,41 More details of the characteristics of the selected studies can be found in Table 1.…”

Section: Diseasementioning

confidence: 99%

Can the Consideration of Societal Costs Change the Recommendation of Economic Evaluations in the Field of Rare Diseases? An Empirical Analysis

et al. 2021

View full text Add to dashboard Cite

“…(6) Cohort‐based Markov models and cohort‐based decision‐analytic model have demonstrated it is cost‐effective to add bedaquiline to a background MDR‐TB treatment regimen…”

Section: Mdr‐tb: Repurposed and Novel Drugsmentioning

confidence: 99%

New drugs and regimens for tuberculosis

et al. 2018

View full text Add to dashboard Cite

Since standardized rifampin-based first-line regimens and fluoroquinolone-based second-line regimens were used to treat tuberculosis (TB), unfortunately without timely modification according to the drug resistance profile, TB and drug-resistant disease are still important public health threats worldwide. Although the last decade has witnessed advances in rapid diagnostic tools and use of repurposed and novel drugs for better managing drug-resistant TB, we need an appropriate TB control strategy and a well-functioning health infrastructure to ensure optimal operational use of rapid tests, judicious use of effective treatment regimens that can be rapidly tailored according to the drug resistance profile and timely management of risk factors and co-morbidities that promote infection and its progression to disease. We searched the published literature to discuss (i) standardized versus individualized therapies, including the choice between a single one-size-fit-all regimen versus different options with different key drugs determined mainly by rapid drug susceptibility testing, (ii) alternative regimens for managing drug-susceptible TB, (iii) evidence for using the World Health Organization (WHO) longer and shorter regimens for multidrug-resistant TB and (iv) evidence for using repurposed and novel drugs. We hope an easily applicable combination of biomarkers that accurately predict individual treatment outcome will soon be available to ultimately guide individualized therapy.

show abstract

Cost-effectiveness of Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the Republic of Korea

Cited by 13 publications

References 17 publications

Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China

Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China

Can the Consideration of Societal Costs Change the Recommendation of Economic Evaluations in the Field of Rare Diseases? An Empirical Analysis

New drugs and regimens for tuberculosis

Contact Info

Product

Resources

About